This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06606106 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 1 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 302 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Overweight; Obesity |
| Interventions | LY3537031; Placebo |
| Start | Sep 5, 2024 |
| Primary completion | Nov 2026 |
| Study completion | Nov 2026 |
| Results posted | Not yet |
| Registry last updated | Sep 30, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants.
Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 49 weeks excluding a screening period.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration | Baseline to Study Completion (Up to 56 Weeks) |
11 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
